PTGX

Protagonist Therapeutics Inc

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported $0.05 earnings per share for the quarter, topping analysts' consensus estimates of ($0.65) by $0.70. The company had revenue of $56.37 million for the quarter, compared to...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) has received an average recommendation of "Moderate Buy" from the fifteen ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a ho...

Jennison Associates LLC bought a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 331,164 shares of the company's stock, v...

M&T Bank Corp acquired a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 11,207 shares of the company's stock, valued at approximately $979,000. Other large investors ha...

Pictet Asset Management Holding SA lessened its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 35.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 529,631 shares o...

Moody Aldrich Partners LLC lessened its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 43.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 80,623 shares of the comp...

UBS Group AG raised its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 46.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,770,021 shares of the company's stock after purchasing a...

Protagonist Therapeutics (NASDAQ:PTGX) will be releasing its Q1 2026 earnings after the market closes on Wednesday, May 6. (View Earnings Report at...

Universal Beteiligungs und Servicegesellschaft mbH boosted its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 26.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 114,036...